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1. SUMMARY 
The c-Src protein is the leading member of the Src family non-receptor tyrosine kinases 
(SFKs) involved in many signalling pathways. The SH3, SH2 and kinase domains of SFK 
members display large sequence and structural similarity. But each SFKs has unique 
sequences called them as Unique domain (UD). This is an intrinsically disordered region and it 
is not clear its function. However, several studies demonstrated that UD is crucial for c-Src 
regulatory activity.  
The aim of this study is discovering drugs that can bind to Unique or adjacent domains of c-
Src. To do that, a Förster resonance energy transfer (FRET) biosensor composed with SH3, 
SH4 and Unique domain of c-Src has been obtained by plasmid transformation, protein 
expression and chromatography purification. FRET pair fluorophores for the biosensor were 
mClover3 (green) and mRuby3 (red). The binding of some drugs caused a change between the 
distance between the two fluorophores in FRET-biosensor leading to measure changes in 
fluorescence spectra. Drugs were classified according to their FRET’s effect. Only two drugs 
presented a pronounced FRET signal (L13B-C2 and L10B-C9). Finally, binding assays were 
performed with the best drugs in order to determine the binding association constant assuming 
that they followed a model of binding 1:1 of protein:ligand. Based on the values obtained, L10B-
C9 presents a higher affinity for the FRET-biosensor than L13B-C2 (mean of 0,0075 vs 
0,006M-1, respectively).   
Keywords: Src kinase, drug screening, Förster Resonance Energy Transfer (FRET), 
fluorescence, binding constant.  
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2. RESUM 
La proteïna c-Src és el membre principal de la família de Src de tirosina-quinases no 
receptores (SFK) involucrades en moltes vies de senyalització. Els dominis SH3, SH2 i 
quinases dels membres de SFK presenten una gran seqüència i similitud estructural, però cada 
SFK té seqüències úniques que les anomenem Unique domain (UD). Aquesta és una regió 
intrínsecament desordenada i la seva funció no està clara. No obstant això, diversos estudis 
van demostrar que el UD és crucial per a l’activitat reguladora de c-Src.  
L’objectiu d’aquest estudi és descobrir medicaments que poden unir-se al UD o adjacents 
de la proteïna c-Src. Per fer-ho, s’ha obtingut un biosensor de transferència d’energia de 
ressonància de Förster (FRET) compost amb el domini SH3, SH4 i UD de la proteïna c-Src 
mitjançant un procés d’expressió en bactèries i de purificació cromatogràfica. Els dos cromòfors 
de FRET pel biosensor van ser mClover3 (verd) i mRuby3 (vermell). Es van analitzar trenta 
fàrmacs utilitzant el biosensor de FRET sintetitzat. La unió d’alguns dels fàrmacs va provocar 
canvis en la distància entre els dos cromòfors del biosensor de FRET, donant lloc a la 
observació de canvis en espectres de fluorescència. Els fàrmacs es van classificar segons el 
seu efecte de FRET. Només dos fàrmacs van presentar una senyal de FRET pronunciada 
(L13B-C2 i L10B-C9). Finalment, es van realitzar assajos d’unió amb els dos millors fàrmacs 
per tal de determinar la seva constant d’unió suposant que aquests seguien un model d’unió 1:1 
proteina:lligand. A partir dels resultats obtinguts, veiem que L10B-C9 presenta una afinitat 
superior per al FRET-biosensor que L13B-C2 (mitjana de 0.0075 vs 0,006M-1, 
respectivament).     
Paraules clau: Src quinasa, cribatge de fàrmacs, Förster Resonance Energy Transfer (FRET), 
fluorescència, constant de binding.   
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3. INTRODUCTION  
3.1. SFK (SRC FAMILY KINASES) AND C-SRC 
Proteins kinases are enzymes which transfer ATP’s terminal phosphate group to specific 
protein substrates such as residues of serine, threonine or tyrosine[1]. Thus, these proteins carry 
out important roles in cell signalling and, as a consequence, many of them are involved in 
various diseases.   
The Src family kinases (SFK) that are non-receptor tyrosine kinase is formed by ten 
proteins: c-Src, Frk, Lck, Lyn, Blk, Hck, Fyn, Yrk, Fgr and c-Yes[2][3][4]. These proteins participate 
in a wide range of processes such as cell division, survival, differentiation and vesicular traffic[5]. 
The structure of SFK presents four Src homology domains: SH1, SH2, SH3 and SH4 in this 
order from the C terminus to N terminus. Also, there is an intrinsically disordered region (IDR) 
called Unique domain (UD), which is different for each member of the SFK[2]. IDR can maintain 
their functionality despite the lack of a well-defined structure even under physiological 
conditions. Intrinsically disordered proteins (IDP) are important in regulatory and cell signal 
pathways[5].  
In this project we work with a construct derived from c-Src, the leading member of SFK. The 
construct studied contains the SH4, Unique and SH3 domains of c-Src[2]. In addition, the 
complete protein has the following intramolecular interactions:  
• SH3 interacts with UD and a polyproline sequence which work as a linker between 
SH2 and SH1 domain[2] (figure 1). 
• SH2 interacts with the Tyr530 of the C-terminal when it is phosphorylated leading 
to a closure of kinase domain and, as a result, the inactivation of c-Src takes 
place[2] (figure 1).   
• c-Src presents a myristylation site by which can bind to lipid membrane. Also, 
SH3, Unique and positive charge of some amino acids of SH4 work out of well for 
lipid interaction[2].  
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• Moreover, residues 60-67 of the unique lipid binding region (ULBR) from the UD 
can also anchor to lipid membrane[6] (figure 1).  
 
 
 
 
 
 
Figure 1. Src structure (extracted image from ref.1)  
3.2. FLUORESCENCE AND FRET 
3.2.1. Fluorescence 
In 1852 G. G. Stokes described fluorescence as a physical phenomenon of emission of light 
by a chemical substance which has absorbed photons or electromagnetic radiation. The light is 
emitted in a longer wavelength compared to the absorbed light because of the loss of energy by 
vibrational relaxations or heat[7]. 
 In particular, the mechanism of fluorescence is based on the absorption of a photon by a 
fluorophore causing the excitation of an electron from its ground state S0, to an excited energy 
level S1. The electron can rise to different vibrational levels on its excited state depending on the 
wavelength of the absorbed photon. As the excited state is very unstable, the electron relaxes to 
its ground state in nanoseconds emitting a photon in a longer wavelength[7] (figure 2).  
 
 
 
 
Figure 2. Jablonski’s diagram 
explaining the effect of fluorescence  
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The substances that can emit light when they are excited are called fluorophores or 
chromophores. 
3.2.2. FRET 
Förster resonance energy transfer (FRET) is a phenomenon that describes the energy 
transfer between two light-sensitive substances known as chromophores. Specifically, part of 
the energy of the excited fluorophore is transferred to a second fluorophore in a non-radiative 
dipole-dipole coupling[7]. In particular, FRET is our main technique to study the interactions 
between our protein and a library of compounds. 
The effect of FRET is visualized by Jablonski’s diagram (figure 3). First, the donor 
(mClover3 in our study) absorbs energy and one electron raises from its ground state S0 to the 
excitation level S1. Then, the energy that is emitted from the donor is used to excite the second 
fluorophore (mRuby3 in our study). Finally, the second fluorophore emits electromagnetic 
radiation at a different wavelength. It is important to highlight that the origin of FRET is not the 
absorption by acceptor of a photon emitted by the donor[7][8].  
 As a result, a reduction in donor’s fluorescence and an increase of acceptor emission 
intensity is observed[8]. 
 
 
 
 
 
 
 
 
 
Figure 3. Jablonski’s diagram explaining the effect of FRET  
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FRET has some conditions in order to occur[7]:  
1. Overlap of the emission spectrum of the donor and acceptor excitation spectrum 
in order to have a sufficient energy coupling between fluorophores. An overlap 
of 30% is enough to have a reliable detection (figure 4).  
2. The distance between the donor and acceptor must be in the range of 1-10 nm. 
3. Right orientation of the dipole vectors of the donor and acceptor.     
4. High quantum yield of the donor. This means that a higher response from the 
donor with the excitation signal, the higher quantum yield.  
 
 
 
 
 
 
 
 
 
Figure 4. FRET overlap spectrum 
The distance between the donor and acceptor is an important parameter because the 
efficiency of FRET (Eq.1) depends on R0, the Förster distance, which describes the distance of 
this pair donor-acceptor when the efficiency is 50% and R is the actual distance between the 
fluorophores[9].  
 
(Eq.1) 
3.3. FRET- BIOSENSOR 
FRET is highly sensitive to the distance between donor and acceptor within the 1-10nm 
range, using this characteristic, FRET-biosensors were designed. They are composed of 
fluorophores and sensing domains and have been widely adopted as spectroscopic rules to 
monitor a variety of biochemical activities that produce changes in molecular proximity, such as 
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protein-protein interactions, conformational changes, intracellular ion concentrations, and 
enzymes activities[10]. The major advantage of them is that they are non-destructive and 
minimally invasive for cells. Depending on whether the two fluorophores are conjoined to the 
same molecules, FRET-biosensors can be classified as intramolecular (donor and acceptor are 
in the same molecule) or intermolecular type (donor and acceptor are in different molecules). It 
is crucial in FRET-biosensor choose optimal FRET pair (donor and acceptor fluorophores)[11].   
An intramolecular FRET-biosensor has been designed by Biomolecular NMR group to study 
the intrinsically disordered region of c-Src. In particular, it includes the SH4, Unique and SH3 
domains flanked by two fluorescent proteins mClover3 (green fluorescent protein) and mRuby3 
(red fluorescent protein) forming a FRET pair (figure 5). These fluorescent proteins are 
characterized by their brightness, photostability and wide range of distance measurable by 
FRET[12][8][13].  
Figure 5. Intramolecular FRET-biosensor. (A) No FRET effect (B) FRET effect due to a conformational 
change caused by internal alterations (blue star) and both fluorescent proteins approach (yellow star).  
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The FRET-biosensor is called CLOBY from Clover and Ruby and its sequence is:  
 
 
 
 
 
 
The green sequence is mClover3 and the red one is mRuby3. Moreover, there’s a His-tag at 
the beginning, the blue sequence indicates the SH3 domain, the pink one the UD and the purple 
SH4 domain. The c-Src sequence is connected with the pair of fluorophores through two linkers 
(yellow sequence).  
The chromophores (figure 6) are originated from a spontaneous post-translational 
modification of three amino acids residues. In figure 6 is observed the structure of each 
chromophore after a post-translational process:  
• mRuby3: Gln66-Tyr67-Gly68 
• mClover3: Ser5-Tyr66-Gly67 
 
 
 
 
 
Figure 6. Chromophore structure of mRuby3 (red chromophore) and mClover3 (green chromophore) 
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3.3.1. Maturation time for fluorescent proteins (Chromophores) 
Fluorescent proteins have become a dominant tool for the exploration of the dynamics and 
localization of the macromolecular contents of living cells. They are used in several biological 
molecular applications[14]. They are fundamental for FRET-biosensor structure. However, 
fluorescent proteins have both advantages and disadvantages. Once a fluorescent protein is 
expressed it has to go through several stages until it becomes functional. These processes are 
known as “maturation”. Until completion of maturation process, the protein, even though already 
synthesized, is not fluorescent. For this reason, it is important to consider the maturation 
process of fluorescent protein to obtain a functional FRET-biosensor[15]. Maturation process for 
mRuby3 and mClover3 has been studied and proposed mechanism has been described to 
produce red or green signals respectively. 
The first steps in the maturation process are common for the two chromophores. Firstly, the 
formation of the chromophore starts with the cyclization of the main chain to form a five-
membered ring intermediate (scheme 1). There is a nucleophilic attack by the pair of electrons 
present on the nitrogen of the amino acid to the carbonyl of the amide (-CONH-) so as to form a 
cycle of five. Moreover, there is a protonation in order to form an alcohol[16].  
 
 
 
 
Scheme 1. Mechanism of maturation of chromophores (cyclation)  
Then, it takes place an oxidation in order to obtain the precursor chromophore (scheme 2). 
Specifically, the hydrogen of a β-carbon is attacked by the oxygen of a water molecule which 
acts as a base in order to form an enolate. The enolate transfers an electron to molecular 
oxygen present in the medium starting a radical reaction which results on the formation of 
peroxy adduct. The peroxy adduct reacts with hydronium ions present in the medium to form the 
hydroperoxy adduct which is unstable. Finally, the hydroperoxy takes a proton from the nitrogen 
present in the ring giving the mature precursor chromophore[17].   
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Scheme 2. Mechanism of maturation of chromophores (oxidation) 
The green chromophore is obtained by an alcohol removal reaction (scheme 3). Specifically, 
an electron pair of oxygen’s water attacks to a hydrogen forming a double bound. Then, the 
alcohol is removed by water’s attack to a hydrogen of the ring. Alcohol is not a good leaving 
group so as to be removed it has to protonated in some step, for instance by hydronium ion. 
Finally, a conjugate structure that represents the green chromophore is obtained. The final 
colour of the chromophore depends on which amino acid is in the chain (R), in the case of green 
chromophore is histidine[17].  
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Scheme 3. Mechanism of maturation of chromophores (formation of green chromophore) 
The red chromophore is obtained by a dehydration on α-hydrogen respect the alcohol 
(scheme 4). First, the alcohol is protonated to become a good outgoing group. Then, an 
elimination reaction takes place when an electron pair of oxygen’s water attacks to the α-
hydrogen respect the alcohol so as to eliminate -OH2+. Finally, the oxygen of a water molecule, 
which acts as a base, removes a proton from the amide, so that the conjugation is obtained and 
the blue intermediate is formed.                       
 
 
 
 
    
Scheme 4. Mechanism of maturation of chromophores (formation of blue intermediate) 
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 Finally, an oxidation from the hydrogen of β-carbon results as the formation of the red 
chromophore (scheme 5). Specifically, a nucleophile attack takes place to oxygen. Then, the 
peroxy adduct (17) acts as a base in order to form an hydroperoxy adduct (18) which is very 
unstable and promote the formation of the red chromophore.  
 
 
 
Scheme 5. Mechanism of maturation of chromophores (formation of red chromophore) 
All the reactions take place in biochemical conditions where some reactions that are not 
normally spontaneous can take place.  
3.4. DRUG BINDING TO FRET-BIOSENSOR  
The accurate determination of binding interactions plays an important role in fields such as 
pharmacology. Binding is often determined by monitoring the response caused by varying one 
of the binding partners in the experiment, the drug (L) in our assay[18]. The binding between a 
protein and its ligand can be represented quantitatively by the flowing expression:  
P + L ⇌ PL  𝐾𝑎 =
[𝑃𝐿]
[𝑃][𝐿]
  (Eq. 2) 
Where P represents the free protein, L the free ligand and PL the complex ligand-protein. 
From this equilibrium, it is possible to establish a constant that describes the relation between 
the quantity of products and the number of reagents (Eq. 2). Ka represents the association 
constant of the complex protein-ligand and it is used as a measure of the affinity of the protein 
for the ligand. A higher value of Ka is synonymous of more affinity from protein to the ligand[19].  
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A graph with the concentration of the free ligand in the X axis versus this relation PL /PT 
is represented so as to obtain the concentration of the complex protein-ligand by equation 4. 
Once PL is known, Ka can be determined by equation 2[19].  
So that to plot fluorescence measures this relation is used:   
[𝑃𝐿]
[𝑃𝑇]
=
𝐹∞− 𝐹
𝐹∞−𝐹𝑜
  (Eq. 3) 
Equation 4 is deduced from the combination of the following relations[19]: 
𝐾𝑎 =
[𝑃𝐿]
[𝑃][𝐿]
               𝐶𝑃 = [𝑃𝐿] + [𝑃]                𝐶𝐿 = [𝑃𝐿] + [𝐿] 
 
[𝑷𝑳]𝟐𝑲 + [𝑷𝑳]𝑲(−𝑪𝑳 − 𝑪𝑷 − 𝟏) + 𝑪𝑳𝑪𝑷𝑲 = 𝟎  (Eq. 4) 
Abstract nomenclature:  
• PL → concentration of complex protein-ligand. 
• P → concentration of free protein. 
• PT → total concentration of protein. 
• L → concentration of free ligand.  
• F → fluorescence at a determinant point. 
• Fo → minimum value of fluorescence. 
• F∞ → highest value of fluorescence.  
• CP → initial protein concentration.   
• CL → initial ligand concentration. 
3.5. STATE OF ART  
High levels of c-Src activity have been related with breast, prostate and colorectal cancer. 
Previous studies achieved by the Biomolecular NMR group managed by Dr. Miquel Pons at 
University of Barcelona have demonstrated the importance of Unique domain as a regulator of 
c-Src activity. This group has proved that the invasive potential effect of a type of colon’s 
cancer’s cells can be reduced by 50% changing a single amino acid in UD[6]. These results 
demonstrate the importance of regulatory roles of disordered domains as well as organized 
regions such as SH1, SH2 and SH3.  
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Previous studies conducted by Biomolecular NMR group allowed to design a FRET-
biosensor called CLOBY in order to study the intrinsically disordered region of c-Src. 
Understanding the regulation of these proteins is important in order to use them as therapeutic 
targets. Specifically, in this project a screening of compounds is done with CLOBY (FRET-
biosensor) in order to know if any of them can interact with SH4, SH3 or the intrinsically 
disordered region of c-Src.    
4. OBJECTIVES 
The main objective of this final degree project is to screen a library of proposed anti-cancer 
compounds on a FRET-biosensor of c-Src and study changes produced between SH4, Unique 
and SH3 domain by FRET variation of two fluorescent proteins anchored to its C-terminal and 
N-terminal. In order to answer this question, a set of specific objectives are defined, as follows: 
• Expression and purification of the construct mClover3-linker-SH3-Unique-SH4-
linker-mRuby3 (FRET-biosensor of c-Src).  
• Test thirty compounds obtained from a library of compounds which was approved 
by the food and drug administration (FDA) and assets for cancer.  
o Classification of compounds according to their FRET’s effect.   
o For FRET’s effect positive compounds, calculation of their binding 
association constant.   
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5. EXPERIMENTAL SECTION 
5.1. MATERIALS AND METHODS 
5.1.1. Materials 
Plasmid pET-19 and the bacterial cell BL21(DE3) are from Novagen. Reagents used in this 
project have been purchased from Sigma Aldrich and Aplichem Panreac. All aqueous solutions 
were prepared using water purified with Millipore BioCell system and also, their compositions 
are shown in Appendix 1. The thirty compounds that had been studied in this project were 
approved by FDA. However, for reasons of intellectual property protection, we cannot provide 
additional information of the same.   
5.1.2. Instrumental 
Instrument Model Software 
Nickel Cartridge affinity column His TrapTM HP 1mL - 
FPLC AKATA FPLC W FRAC-950 Unicom 5.20 
UV-Vis Spectrophotometer Shimadzu UVmini-1240 UV Probe 2.42 
Fluorimeter   Photon Technology International Felix32TM 
5.2. SYNTHESIS OF THE FRET-BIOSENSOR 
In order to synthesize the biosensor, three different steps have been performance: 
transformation, expression and purification.   
5.2.1. Transformation  
The DNA can be transfected into bacteria by transformation method (figure 8). Circular DNA 
fragments, which are called plasmids, contain the genes for the biosensor as well as the genes 
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that encode resistance to certain antibiotics, such as ampicillin (figure 7). Therefore, a selective 
medium containing an antibiotic was used so that only cells that contain the gene that encodes 
the resistance of a specific antibiotic can grow. In particular, the plasmid used was pET-19 
(Novagen) and the bacterial cell line was BL21(DE3) (Novagen). This transformation was 
achieved by adding DNA plasmid to a cell stock of competent cells in an Eppendorf microtube of 
1mL (normally 1μL from plasmid stocks between 80-100ng/μL). Then, cells were placed for 
1minute 30seconds at 42 ̊C in a water bath. In these conditions, pores were formed in the 
membrane allowing DNA to enter into the cell. After that, cells were placed back in ice for 
2minutes. Transformed cells can be stored as glycerol stocks at - 80 ̊C.  
 
     
 
 
 
 
Figure 7. Structure of pET-19            Figure 8. Protein transformation  
5.2.2. Protein Expression  
The protein expression starts from glycerol stocks already prepared in the previous step.   
Firstly, a pre-culture step was done. It consists in amplifying a cell stock during an overnight 
period before starting a large scale growing (expression). In one falcon tube of 50mL, luria broth 
(LB) previously autoclaved was added (10mL*Number of expression flasks) with the 
corresponding antibiotic, in our case ampicillin (10μL*Number of expression flasks). Then, it was 
divided into the necessary falcon tubes to avoid a poor growth produced by a bad oxygenation. 
About 40μL of the aliquot of glycerol stocks was added to each falcon tube. Finally, these falcon 
tubes were left shaking at 37 ̊C overnight.  
The next day, the content of the two falcon tubes was added to 2L flask of LB culture 
medium which had been previously autoclaved. Then, ampicillin was mixed in the flask (1μL of 
antibiotic for each mL of water). These cultures were incubated at 37 ̊C at 140rpm until the 
optical density (OD) at 600nm was 0.6 approximately. After, the protein expression was induced 
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by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 1mM. When 
the induction started, cultures were incubated at 25 ̊C at 140rpm until were totally maturated 
(figure 9). In order to obtain the protein, cultures were centrifugated at 4500rpm for 20minutes at 
4 ̊C and the supernatant was removed. In a sterile 50mL falcon tube, the remaining pellet was 
resuspended with lysis buffer, 500μL of protease inhibitor cocktail (PiC), 500μL of 
phenylmethylsulfonyl fluoride (PMSF) and stored at -80 ̊C till the start of purification.   
 
 
 
 
 
 
Figure 9. Guide of cell cultures: A) proper maturation of fluorescent proteins B) not enough maturation 
yet C) particles in suspension (NO maturation yet) D) LB after autoclave 
5.2.3. Protein Purification 
The resuspended pellet, obtained in the expression protocol, was thawed in a bucked with 
water in the cold room at 4 ̊C. When it was thawed, dithiothreitol (DTT) was added at a 
concentration of 1mM. Then, the pellet was sonicated for 1minute 30seconds in intervals of 10 
seconds repeating it three times. After that, a DNAase aliquot was added at a final 
concentration of 1M and the sample was centrifuged at 20000rpm for 20minutes. This step 
was done to obtain the supernatant with the desired protein and discard cells organelles and 
membrane’s debris from the pellet. 
The supernatant was purified using the Nickel Cartridge affinity column which was 
connected to a peristaltic pump to produce a flux through the column and capture the protein of 
interest. Specifically, the desired protein has strong interaction with immobilized metal ion 
matrices due to its six consecutive histidine. After the protein was kept for Nickel column, it was 
eluted using a characteristic elution buffer that contains a high concentration of imidazole which 
competes for the active binding site and releases the protein from the column.  
After the first purification, the sample was introduced into the fast protein liquid 
chromatography (FPLC) in order to separate the purest fractions of the desired protein. This is a 
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size exclusion chromatography. Before to start, it is important to condition the column with 
NaOH, water and buffer F which is going to be used to separate the protein for its biological 
characterises. When the chromatography was finished, only those fractions, that represent the 
relevant peak in the obtained chromatogram, were collected and analysed by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to identify the purest fractions. This part 
consists in denaturalising the protein by loading buffer before being introduced in the SDS-gel. 
In particular, one of the components of the loading buffer is SDS. Therefore, the presence of 
SDS in the sample allows to charge proteins with a negative charge in order to separate by their 
molecular weight with an electrophoretic method.  By the SDS-PAGE gel, the purest fractions of 
the FRET-biosensor called Cloby were identified.  
5.3. CONCENTRATION MEASURE  
Analysis of the absorbance caused by chromophores was measured by UV-Vis 
spectrophotometer from 250nm to 650nm in order to calculate the concentration of the protein 
and each of its chromophores by Beer-Lambert’s law:   
𝑨 = 𝒍 ×  × 𝑪 
In particular, A represents the amount of light absorbed by the sample at a certain 
wavelength,  the molar absorptivity, l the distance of the cuvette which is 0.1cm and C the 
concentration of the absorbent species.   
Aromatic residues such as tryptophan and tyrosine had an absorption maxim at 280nm. The 
chromophores of the fluorescent protein had maxim at 506nm for mClover3 and 558nm for 
mRuby3.   
5.4. FRET ASSAY 
Fluorescence’s spectrums were measured by the fluorimeter of Photon Technology 
International (PTI) and processed with spectroscopy software called Felix 32TM. The lamp of the 
fluorimeter was a mercury’s lamp.  
Screening analysis was performed with a ratio of 9:1 Buffer(FRET-Biosensor):DMSO(Drug) 
and the samples were prepared in Eppendorf microtubes. The concentration of FRET-Biosensor 
was 1μM and the final concentration of the solution was 100μM. As a control, a blank was done 
with a ratio of 9:1 Buffer:DMSO(Drug). So as to obtain data, samples were introduced into a 
quartz cuvette Hellma 8mm × 2mm. 
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In order to visualize the FRET phenomenon, the sample was excited at the wavelength of 
mClover3 (506nm) and then, emission spectrum was observed between 516nm-650nm. 
Therefore, the emission spectra of mClover3 and mRuby3 were obtained.   
The excitation and emission wavelength for each chromophore is respectively is:  
• Excitation: 
o mClover3: 506 nm 
o mRuby3: 558 nm 
• Emission:  
o mClover3: 518nm  
o mRuby3: 592nm  
5.5. BINDING ASSAY  
Binding assay was also done with the fluorimeter of Photon Technology International (PTI) 
and processed with spectroscopy software called Felix 32TM.  
In this case, solutions from the range of 100μM to 0,1μM were prepared with a ratio of 9:1 
Buffer(FRET-Biosensor):DMSO(Drug) with a constant concentration of FRET-Biosensor 1μM. 
To obtain data, samples were introduced into a quartz cuvette Hellma 8mm × 2mm. Also, the 
sample was excited at the wavelength of mClover3 (506nm) and then, the emission spectrum 
was observed from 516nm just 650nm.  
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6.RESULTS AND DISCUSSION 
6.1. FRET-BIOSENSOR SYNTHESIS AND PURIFICATION 
In order to confirm that the FRET-biosensor was correctly obtained, some tests had been 
realized such as mass spectrometry and SDS-PAGE gel into the different column fractions: 
flow-through fraction (FT), wash fraction (W), elution fraction (E) and several column factions 
(D9-E7).     
6.1.1. SDS-PAGE gel 
SDS-PAGE gel is a very common method for separating proteins of interest, due to the size 
protein, by electrophoresis. In this project, it was used to identify the purest fractions of protein 
purification and therefore, verify if the purification had been correctly done.  
As already explained, firstly the FRET-biosensor was purified by a nickel affinity column and 
some fractions were collected (FT, W and E).  Then, the elution fraction (E) which contained the 
desired protein was completely purified by the FPLC. According to the obtained chromatogram 
(figure 10), fractions of the main peak were chosen (D9-E7). Then, an SDS-PAGE gel was done 
to choose only the fractions in which not impurities were observed. The SDS-PAGE gel is 
shown in figure 11. 
The flow-through fraction (FT) was obtained when the impure protein was loaded inside the 
nickel affinity column. In this fraction, we observed several brands that were the whole cell 
expression that had not interact with the column. In the wash fraction (W), there were four 
clearly brands. One band corresponded to the desired protein and the other three bands were 
proteins with non-specific interactions with the column. Finally, in the elution fraction (E) the 
desired protein was totally eluted because the elution buffer contained high concentration of 
imidazole (400mM) that released the desired protein from Ni-NTA column due to the presence 
of six consecutive histidine in the desired protein. In figure 11, the circle of the SDS-PAGE gel 
indicates the positive band for the desired protein.  
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According to SDS-PAGE gel, fractions of D10 to E1 were the purest because they had the 
positive band, the desired protein. The molecular marker (M) is used to identity approximately 
the zone where the protein has to be located depending on its molecular weight.  Moreover, in 
the SDS-PAGE gel we observed a degradation zone. This was confirmed by FPLC (figure 10). 
In FPLC spectra, we could observe a big peak of the desired protein (FRET-biosensor, CLOBY) 
and another zone just closer that corresponded a degradation of the protein. This degradation 
was caused for the partial maturation of the chromophores.   
 
.  
 
 
 
 
 
 
 
 
 
Figure 10. FPLC spectra of FRET-biosensor 
 
 
 
 
 
 
 
 
 
Figure 11. SDS-PAGE gel showing the purification of FRET-biosensor 
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6.1.2. Mass Spectrometry Analysis (LC-MS) 
The purest fraction obtained by the FPLC was concentrated in order to send it to analyse by 
mass spectrometry.  
Based on the mass spectrum obtained (figure 12), it was observed a significant peak of high 
abundance which coincided with the molecular weight of the biosensor taking into account the 
loss of some molecules by a post translational process (scheme 6) in order to convert the 
FRET-biosensor into a fluorescent substance.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 6. Maturation reactions of chromophores 
Specifically, the molecular weight of the protein is 72.68 kDa. Considering this loss, the final 
molecular weight of the biosensor is:  72680-20-18= 72642 Da. That value matches with the 
significant peak of the mass spectrum. With this result, we can conclude that FRET-biosensor 
has been synthesize and purified correctly.   
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Figure 12. Mass spectrometry results of FRET-biosensor 
6.2. MATURATION OF THE CHROMOPHORES 
As already explained, in order to obtain the fluorescent protein a maturation’s process takes 
place in some steps. The maturation mechanism is spontaneous and also time dependent, 
between two or three days are necessary to obtain the complete chromophores’ maturation.   
A quantitative evidence in order to determine the final concentration of each chromophore 
was done by an analysis UV-Vis. The results are shown in table 1.  
 
 
 
Table 1. Final concentration for FRET-biosensor and each chromophore at its wavelength 
With these results, we can conclude that there was a fraction of mRuby3 that was not totally 
maturated. Therefore, we can conclude that maturation of mRuby3 is more complicated than 
mClover3 because more steps are necessary such as two oxidations. A correct oxygenation of 
the flasks could be an option to solve that issue.  
 
 
 
 FRET-biosensor mClover3 mRuby3 
Wavelength nm 280 506 556 
Molar absorptivity  mM-1cm-1 66.24 109 128 
Final concentration % 100 90-87 62-55 
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6.3. FRET ASSAY 
As already explained, the objective of this part was to screen a library of thirty compounds in 
order to detect FRET variation of mRuby3 and mClover3 because of changes produced 
between SH4, Unique and SH3 domains.   
In particular, the screening of the thirty compounds consisted in measuring the fluorescence 
emission of FRET-biosensor from 516nm to 650nm. The sample was excited at the wavelength 
of mClover3 (506nm) so as to plot the intensity emission as a function of wavelength.  
In addition, for each compound, a control of FRET-biosensor with Tobacco Etch Virus (TEV) 
was done in order to have a control with no FRET to confirm the absence of interactions 
between drugs and the fluorescent proteins. In particular, TEV is a protease which cuts the 
amino acid sequence of proteins. Also as another control, a screening of the blank of drugs was 
done with the aim to analyse if any of them present absorbance in the region to study. No one of 
the compounds that tested positive in the FRET’s study had absorbance in that region.  
Based on the results of the screening, compounds had been classified according to their 
FRET’s effect (table 2). In particular, they were organized in two groups: the active compounds 
which presented a FRET’s effect and the inactive compounds that no FRET’s effect was 
observed. The group of active compounds was classified in two subgroups according to the 
difference of fluorescence’s signal between the FRET-biosensor and the compound + FRET-
biosensor at the wavelength of mRuby3.  
 
 
 
 
 
 
 
 
Table 2. Classification of the thirty compounds according to FRET’s effect 
ACTIVE COMPOUNDS INACTIVE COMPOUNDS 
L13B-C2 
L10B-C9 
(236862 - 116404 counts/s) 
Pronounced FRET’s effect 
L04B-D2 
L06B-B2 
L06B-F1 
L06B-F7 
L06B-F9 
L08B-H8 
L10B-A10 
L10B-E9 
L11B-H9 
L12B-B2  
L13B-C2 
L13C-D2 
L14C-D2 
L14B-G1 
L15B-F1 
L15B-H8 
L16B-A10 
L17B-B9 
L17B-G1 
L17B-G10 
L17B-H10 
L18B-B7 
L18B-C2 
L17B-C2 
L06B-F9 
L16B-H9 
L17B-H9 
L18B-H7 
(81290 - 50311 counts/s) 
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To explain this classification, the most representative results are showed below.   
The figure 13 shows an example of an inactive compound. No effects were observed, so the 
profile of the compound was the same as FRET-biosensor. Moreover, in figure 14 it was 
observed the same effect for the control with FRET-biosensor TEV. With these results we 
conclude that the presence of this type of compounds do not cause any effect to the protein. 
Therefore, there is not approximation between donor and acceptor chromophore.    
 
 
 
 
 
 
 
 
 
 
Figure 13. Excitation and emission spectrum of L15B-H8 + FRET-biosensor 
 
 
 
 
 
 
 
 
 
 
Figure 14. Excitation and emission spectrum of L15B-H8 TEV + FRET-biosensor 
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On the other hand, two compounds were found to present a pronounced FRET’s effect with 
a wide range of fluorescence signal at the wavelength of mRuby3 (point 2) (236862 - 116404 
counts/s). First, it is important to highlight that the first raised signal is from the chromophore 
mClover3 and the second signal is from mRuby3.  
In figure 15 was observed that while fluorescence of donor was reduced (point 1), 
fluorescence of the acceptor was increased (point 2) when the drug was added in the FRET-
biosensor (blue line). Therefore, a FRET’s effect was observed because part of the energy of 
the excited chromophore (mClover3) was transferred to the second chromophore (mRuby3). 
However, the location of the drug in the FRET-biosensor was not known. With this result, we 
can only affirm that there is an approximation between the two chromophores.  
  
 
 
 
 
 
 
 
 
 
Figure 15. Excitation and emission spectrum of L13B-C2 + FRET-biosensor 
Analysing the spectrum of the former compound with TEV (figure 16), there was an 
important decrease of the FRET signal. Specifically, there was a little change on the 
fluorescence of the donor which was reduced (point 1) and also the fluorescence of the 
acceptor changed (point 2) compared to figure 15.  
With these results we can conclude that there is a less FRET’s effect when the protein was 
cut by TEV. From this control we could suppose that the tendency to react between the drug 
and the FRET-biosensor was higher when it was fully connected.  
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This diminished FRET’s effect could be caused by these two reasons:  
• TEV could not be 100% efficient. Therefore, there is still complete protein in the 
medium which can suffer FRET.  
• Drug could interact directly to donor or acceptor modifying the system. Therefore, 
chromophores may interact in spite of the FRET-biosensor being cut.  
An example of an active compound in the range (81290 - 50311 counts/s) is shown in 
Appendix 2.  
 
 
 
 
 
 
 
 
 
Figure 16. Excitation and emission spectrum of L13B-C2 TEV + FRET-biosensor 
6.4. BINDING ASSAY 
In this experimental part, a binding assay of the two compounds that presented a 
pronounced FRET’s effect (L13B-C2 and L10B-C9) was done with two replicates for each case. 
The experiment was performed with a range of drug’s solutions from 100M to 0,1M with a 
constant concentration of FRET-biosensor 1M.  
Based on the intensity obtained with the fluorimeter, we decided to focus the study at the 
emission wavelength of mClover3 (518nm) and mRuby3 (592nm). All samples had been 
represented by (F∞-F/ F∞-Fo) versus drug concentration L at a certain wavelength 518nm and 
592nm.  
The figure 17 shows the results of L10B-C9 at a wavelength of 518nm. Analysing the graph, 
two zones were clearly visible. Firstly, there was a first zone (from 0M to 10M) with a 
negligible effect of the drug on the observed fluorescence. From 10M there was a strong 
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response that could be fitted to an apparent 1:1 model of binding. The abrupt change in 
response around 10M was reminiscent of the response of compounds forming micelles and 
the critical concentration at which the changes were observed would correspond to the critical 
micelle concentration (CMC). L10B-C9 is a highly hydrophobic molecule with a single charge 
and a low aqueous solubility. Thus, the hypothesis that the active species was actually a 
micellar form of L10B-C9 is reasonable.  
 
 
 
 
 
 
 
 
 
Figure 17. L10B-C9 curve form 0M to 100M at 518nm 
The figure 18 shows the results of L10B-C9 at a wavelength of 592nm. Fluorescence at 
592nm, when exciting at 506nm, was mainly the result of FRET and reflected the proximity of 
the FRET-biosensor. However, changes in the fluorescence of the donor would also affect the 
observed fluorescence at 592nm: bellow 10M there was a negligible response. Above 10M 
the fluorescence at 592nm was dominated by a strong FRET suggesting that interaction of the 
sensor with L10B-C9 (micelles) reverted in the approximation of the two fluorescent proteins.  
The profile of the curve in the figure 18 did not adjust to a quadratic equation and therefore, 
the binding constant could not be determined.   
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Figure 18. L10B-C9 curve form 0M to 100M at 592nm 
The compound L13B-C2 showed the same profile as L10B-C9 in each wavelength. Its 
graphs are shown in Appendix 2.  
Assuming that the second zone (10M to 100M) of the graph at 518nm followed a model’s 
binding with a relation 1:1 protein:ligand, an approximate calculation of the apparent binding 
constant was done. First, the value of effective concentration was determined by subtracting the 
value of the actual concentration minus CMC. Then, the curve may be adjusted to a second-
degree equation (figure 19). From this equation, the concentration of protein-ligand was 
determined and finally the binding association constant for each replicate was calculated. Then, 
the average of both replicates was calculated and its respective standard error of the mean 
(SEM).  
 
 
 
 
 
 
 
 
       Figure 19. L10B-C9 curve form 0M to 100M at 518nm (effective concentration) 
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The results of all experiments which have been performed are shown in table 3. 
 
 
 
 
 
Table 3. Results of the binding assay 
According to the results of table 3, we may conclude that a part of our data fits to the binding 
model 1:1. In addition, after the analysis of the obtained values, we may conclude that L10B-C9 
presents a higher affinity for the FRET-biosensor than L13B-C2 because the binding association 
constant is higher. The standard error of the mean for L13B-C2 was 33%, so the mean 
calculated is far from the real value of the real association constant. If we would be able to carry 
out more replicates, this error could be diminished.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DRUG BINDING ASSOCIATION CONSTANT 
Assay 1 Assay 2 Mean 
L10B-C9 0,0077 0,0072 (0,0075±0,0003) M-1 → 4% SEM 
L13B-C2 0,008 0,003 (0,006±0,002) M-1 → 33% SEM 
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7. CONCLUSIONS 
The main conclusions that are obtained from this research are:  
• The construct mClover3-linker-SH3-Unique-SH4-linker-mRuby3 (FRET-biosensor 
of c-Src) has been correctly expressed and purified, mass spectrum confirms it.  
• The screening of compounds was successfully done. FRET has been studied with 
a wide range of drugs which have been classified according to that effect. Two 
compounds (L10B-C9 and L13B-C2) interact with the FRET-biosensor causing a 
spectacular FRET’s effect.  
• The interaction between these two former drugs and FRET-biosensor seems to 
take place when a minimum concentration of the drug is added. Probably, the 
active specie is actually a micellar form of the drug.   
• Assuming a binding model protein-ligand 1:1, the compound L10B-C9 presents a 
higher affinity for the FRET-biosensor than L13B-C2.  
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9. ACRONYMS 
CLOBY  Clover Ruby  
DNA   Deoxyribonucleic Acid  
DTT   Dithiothreitol  
FDA   Food and Drug Administration  
FPLC  Fast Protein Liquid Chromatography 
FRET  Förster Resonance Energy Transfer 
IDP   Intrinsically Disorder Region 
IDR   Intrinsically Disorder Region 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
LB   Luria Broth  
LC-MS  Liquid Chromatography-Mass Spectrometry  
OD   Optical Density 
PiC   Protease Inhibitor Cocktail 
PMSF  Phenylmethylsulfonyl Fluoride 
PTI   Photon Technology International 
SDS-PAGE  Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
SFK   Src Family Kinases 
TEV   Tobacco Etch Virus 
UD   Unique Domain  
ULBR  Unique Lipid Binding Region  
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APPENDIX 1: BUFFERS 
− Lysis Buffer (pH 8) to 1L  
 
Reagent Concentration 
TRIS-HCl 20mM 
NaCl 300mM 
Imidazole 10mM 
NaN3  0.01% 
 
− Elution Buffer (pH 8) to 50 mL 
The elution buffer is prepared by adding imidazole at a final concentration 400 mM 
to lysis buffer.   
 
− Buffer F (pH 7.5) to 1L 
Reagent Concentration 
NaH2PO4 0.2M 
Na2HPO4 0.2M 
NaCl 150mM 
EDTA 0.2mM 
NaN3  0.01% 
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APPENDIX 2: GRAPHS’ FRET - BINDING ASSAY  
• L17B-C2  
 
 
  Figure 20. Excitation and emission spectrum of L17B-C2 + FRET-biosensor 
 
 
 
 
 
 
       Figure 21. Excitation and emission spectrum of L17B-C2 TEV + FRET-biosensor 
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• L13B-C2  
 
 
 
 
 
 
 
 
 
 
Figure 22. L13B-C2 curve from 0M to 100M at 518nm  
 
 
 
 
 
 
 
Figure 23. L13B-C2 curve from 0M to 100M at 592nm 
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Figure 24. L13B-C2 curve from 0M to 100M at 518nm (effective concentration) 
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